News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
749,301 Results
Type
Article (45625)
Company Profile (339)
Press Release (703319)
Multimedia
Podcasts (141)
Webinars (21)
Section
Business (212944)
Career Advice (2200)
Deals (37248)
Drug Delivery (132)
Drug Development (84617)
Employer Resources (178)
FDA (16979)
Job Trends (15676)
News (361352)
Policy (34651)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2644)
Accelerated approval (32)
Adcomms (33)
Allergies (145)
Alliances (52225)
ALS (175)
Alzheimer's disease (1703)
Antibody-drug conjugate (ADC) (335)
Approvals (17216)
Artificial intelligence (538)
Autoimmune disease (152)
Automation (37)
Bankruptcy (378)
Best Places to Work (11842)
BIOSECURE Act (22)
Biosimilars (200)
Biotechnology (195)
Bladder cancer (158)
Brain cancer (59)
Breast cancer (648)
Cancer (4902)
Cardiovascular disease (428)
Career advice (1854)
Career pathing (39)
CAR-T (287)
CDC (50)
Celiac Disease (2)
Cell therapy (763)
Cervical cancer (36)
Clinical research (72061)
Collaboration (1767)
Company closure (5)
Compensation (1164)
Complete response letters (66)
COVID-19 (2807)
CRISPR (95)
C-suite (847)
Cystic fibrosis (149)
Data (6221)
Decentralized trials (2)
Denatured (41)
Depression (138)
Diabetes (516)
Diagnostics (6788)
Digital health (44)
Diversity (13)
Diversity, equity & inclusion (46)
Drug discovery (256)
Drug pricing (218)
Drug shortages (34)
Duchenne muscular dystrophy (232)
Earnings (92238)
Editorial (60)
Employer branding (21)
Employer resources (157)
Events (121397)
Executive appointments (994)
FDA (20108)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (23)
Funding (1484)
Gene editing (205)
Generative AI (48)
Gene therapy (619)
GLP-1 (1075)
Government (4879)
Grass and pollen (7)
Guidances (385)
Healthcare (19203)
HIV (57)
Huntington's disease (45)
IgA nephropathy (85)
Immunology and inflammation (275)
Immuno-oncology (58)
Indications (104)
Infectious disease (3079)
Inflammatory bowel disease (194)
Inflation Reduction Act (14)
Influenza (110)
Intellectual property (247)
Interviews (344)
IPO (17086)
IRA (57)
Job creations (4175)
Job search strategy (1560)
JPM (68)
Kidney cancer (16)
Labor market (84)
Layoffs (601)
Leadership (37)
Legal (8577)
Liver cancer (93)
Longevity (15)
Lung cancer (659)
Lymphoma (377)
Machine learning (43)
Management (62)
Manufacturing (819)
MASH (171)
Medical device (13890)
Medtech (13942)
Mergers & acquisitions (21233)
Metabolic disorders (1360)
Multiple sclerosis (162)
NASH (20)
Neurodegenerative disease (330)
Neuropsychiatric disorders (95)
Neuroscience (2968)
Neurotech (1)
NextGen: Class of 2026 (6734)
Non-profit (4584)
Now hiring (65)
Obesity (663)
Opinion (305)
Ovarian cancer (166)
Pain (215)
Pancreatic cancer (225)
Parkinson's disease (291)
Partnered (34)
Patents (500)
Patient recruitment (480)
Peanut (59)
People (61385)
Pharmaceutical (100)
Pharmacy benefit managers (33)
Phase 1 (22481)
Phase 2 (31629)
Phase 3 (23694)
Pipeline (5151)
Policy (310)
Postmarket research (2687)
Preclinical (9480)
Press Release (68)
Prostate cancer (240)
Psychedelics (49)
Radiopharmaceuticals (287)
Rare diseases (871)
Real estate (6414)
Recruiting (71)
Regulatory (25693)
Reports (51)
Research institute (2457)
Resumes & cover letters (372)
Rett syndrome (27)
RNA editing (18)
RSV (83)
Schizophrenia (155)
Series A (246)
Series B (190)
Service/supplier (14)
Sickle cell disease (99)
Special edition (26)
Spinal muscular atrophy (163)
Sponsored (42)
Startups (3833)
State (2)
Stomach cancer (19)
Supply chain (111)
Tariffs (100)
The Weekly (98)
Vaccines (1038)
Venture capital (92)
Weight loss (454)
Women's health (88)
Worklife (19)
Date
Last 7 days (616)
Last 30 days (2073)
Last 365 days (30623)
2026 (2909)
2025 (31088)
2024 (36146)
2023 (40929)
2022 (52114)
2021 (56674)
2020 (55108)
2019 (47821)
2018 (36139)
2017 (33569)
2016 (33169)
2015 (39008)
2014 (32960)
2013 (28077)
2012 (30165)
2011 (30871)
2010 (28889)
Location
Africa (828)
Alabama (84)
Alaska (7)
Arizona (314)
Arkansas (14)
Asia (43124)
Australia (6847)
California (11267)
Canada (3285)
China (1144)
Colorado (477)
Connecticut (473)
Delaware (338)
Europe (92812)
Florida (1691)
Georgia (354)
Hawaii (3)
Idaho (61)
Illinois (873)
India (65)
Indiana (529)
Iowa (22)
Japan (432)
Kansas (125)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1392)
Massachusetts (8116)
Michigan (323)
Minnesota (628)
Mississippi (5)
Missouri (125)
Montana (31)
Nebraska (28)
Nevada (125)
New Hampshire (78)
New Jersey (3012)
New Mexico (31)
New York (2972)
North Carolina (1502)
North Dakota (8)
Northern California (5474)
Ohio (334)
Oklahoma (22)
Oregon (47)
Pennsylvania (2278)
Puerto Rico (23)
Rhode Island (47)
South America (1196)
South Carolina (66)
South Dakota (1)
Southern California (4380)
Tennessee (174)
Texas (1746)
United States (40153)
Utah (338)
Vermont (1)
Virginia (274)
Washington D.C. (82)
Washington State (925)
West Virginia (4)
Wisconsin (112)
Wyoming (2)
749,301 Results for "biosyent pharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
BioSyent Declares First Quarter 2026 Dividend
January 30, 2026
·
1 min read
Press Releases
BioSyent Declares Fourth Quarter 2025 Dividend
November 21, 2025
·
1 min read
Press Releases
BioSyent Releases Financial Results for Q3 and YTD 2025
November 21, 2025
·
6 min read
Press Releases
BioSyent Schedules Q3 and YTD 2025 Earnings Release for November 20, 2025
November 14, 2025
·
1 min read
Press Releases
BioSyent Declares Third Quarter 2025 Dividend
August 22, 2025
·
1 min read
Press Releases
BioSyent Releases Financial Results for Q2 and H1 2025
August 22, 2025
·
5 min read
BioSyent In-Licenses Endocrinology Product for Canada
BioSyent Inc. is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc., has entered into an agreement with a European partner for an exclusive license to register, market, sell and distribute a new endocrinology product in Canada.
June 12, 2024
·
2 min read
Business
BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. (“BioSyent Pharma”), has extended its Exclusive License and Distribution Agreement with its European partner for the RepaGyn® and Proktis-M® products, extending BioSyent Pharma’s exclusive Canadian rights to these products until 2032.
April 15, 2024
·
2 min read
Japan
Japanese Pharmas Looking Beyond Borders for M&A to US, EU
Long a quieter, locally focused industry, Japanese pharma giants are increasingly looking to the rest of the world for deals.
December 10, 2025
·
7 min read
·
Dan Samorodnitsky
Press Releases
As mental health patients turn to AI chatbots, how can pharma lead the way?
A new report by Bryter released today reveals where pharma can lead as patients turn to (and question) AI tools for mental health.
February 5, 2026
·
1 min read
1 of 74,931
Next
